- Trial phase
- Approved (pivotal Phase 3 ASCEMBL completed; additional Phase 2/3 studies mostly completed or terminated)
- Time to market
- Already marketed, FDA approval recorded October 29, 2021 (local FDA-catalyst ledger); commercial launch has been under way since.
- Why 4/10
- Scemblix is already approved and commercializing (FDA approval recorded 2021-10-29) with no pending regulatory decision or dated pivotal readout visible in available data, so no hard binary catalyst exists in the next ~12 months, which caps the score in the 3-5 band for an approved drug.
Price Chart
Executive Summary
Scemblix is Novartis' (NYSE: NVS) first-in-class oral CML drug, approved by the FDA on Oct 29, 2021, and one of the company's fastest-growing products: Q2 2026 net sales grew +89% in constant currency per Novartis' July 2026 earnings filing, alongside Kisqali (+43%) and Kesimpta (+32%). It is, however, one product inside a ~$285B mega-cap whose Q2 net sales were $14.4B, so drug-level news moves the stock only modestly; analyst consensus on NVS is 'hold' (mean 2.83) with a price-target mean of $157.15 vs. a ~$157-160 share price, and short interest is negligible (~0.27% of estimated shares outstanding).
How It Works
Scemblix (asciminib, development code ABL001) is an oral, first-in-class treatment for chronic myeloid leukemia (CML), a cancer of the blood-forming bone marrow. CML is driven by the BCR-ABL fusion protein, and asciminib blocks it via a different binding approach than the older tyrosine kinase inhibitor (TKI) drugs, which is why it is used in patients who have already been treated with two or more TKIs (per the pivotal trial design) and whose disease stopped responding to them.
Trial Status
The pivotal Phase 3 ASCEMBL trial (NCT03106779, asciminib vs bosutinib in chronic-phase CML patients previously treated with 2+ TKIs, n=233) is COMPLETED with results. A Phase 3 treatment-optimization study in >=3rd-line CML (NCT04948333) is COMPLETED. A Phase 3 asciminib+imatinib consolidation/TFR study (NCT05413915) and two Phase 2 studies (NCT04216563, NCT03874858) were TERMINATED; a Phase 2 asciminib±imatinib combo study (NCT03578367) is COMPLETED.
The Two-Sided Case
Upcoming Catalysts
- No dated drug-level catalyst identified in available data, external web (which could confirm any 2025-26 label-expansion PDUFA/readout) was down all session; treat any first-line CML expansion timeline as unverified.
- Watch Novartis quarterly 6-K reports (next after Q3 2026) for Scemblix sales trajectory and any label-expansion announcements.
- Watch Phase 3/Phase 2 asciminib trial status changes in ClinicalTrials.gov records (several remain listed as completed without posted results).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report